Advancing Transplantation Outcomes in Children (NCT06055608)
Advancing Transplantation Outcomes in Children (CTOT-41)
🩺 Plain-English Summary (8th-Grade Level)
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham (Site # 71038) — Birmingham, Alabama
Age range: 13 Years to 20 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- University of Alabama at Birmingham (Site # 71038) — Birmingham, Alabama
- Children's Hospital of Los Angeles (Site #: 71036) — Los Angeles, California
- Cedars-Sinai Medical Center (Site #: 71026) — Los Angeles, California
- Mattel Children's Hospital, UCLA (Site #: 71012) — Los Angeles, California
- UCSD Rady Children's Hospital (Site #: 71037) — San Diego, California
- Children's Hospital of Colorado (Site #: 71019) — Aurora, Colorado
- Nemours Children's Health (Site #: 71042) — Wilmington, Delaware
- Children's National Medical Center (Site #: 71039) — Washington D.C., District of Columbia
- Ann and Robert H. Lurie Children's Hospital of Chicago (Site #: 71016) — Chicago, Illinois
- Johns Hopkins Children's Center (Site #: 71025) — Baltimore, Maryland
- Boston Children's Hospital (Site #: 71001) — Boston, Massachusetts
- Helen DeVos Children's Hospital (Site #: 71035) — Grand Rapids, Michigan
- Washington University/St. Louis Children's Hospital (Site #: 71006) — St Louis, Missouri
- New York Medical College/Boston Children's Health Physicians — Westchester, New York
- Duke University (Site #: 71033) — Durham, North Carolina
- Cincinnati Children's Hospital Medical Center (Site #: 71017) — Cincinnati, Ohio
- Children's Hospital of Philadelphia (Site #: 71091) — Philadelphia, Pennsylvania
- UPMC Children's Hospital of Pittsburgh (Site #: 71008) — Pittsburgh, Pennsylvania
- Texas Children's Hospital (Baylor) (Site #: 71005) — Houston, Texas
- Seattle Children's Hospital (Site #: 71041) — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (205) 638-9781
Email: whouse@uabmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study — Pittsburgh, Pennsylvania
- Pro-active Genetic Testing in Kidney Transplant Patients — Scottsdale, Arizona
- Dapagliflozin in Living-Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Phenotype Guided Vasoactive Medication During Kidney Transplantation — Los Angeles, California
- GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial — Livingston, New Jersey
- Letermovir for R+ Study — Madison, Wisconsin
Explore by condition: All Kidney Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.